Form 4: Senti Biosciences Director Fran Schulz Granted 21,950 Stock Options

Senti Biosciences, Inc. Director Fran Schulz was granted 21,950 stock options with an exercise price of $2.05, aligning her interests with shareholder value.

Summary

• Fran Schulz, a Director of Senti Biosciences, Inc. (SNTI), was granted 21,950 stock options.
• The options have an exercise price of $2.05 per share.
• The grant date for these options was June 25, 2025.
• The options are set to expire on June 24, 2035.
• Vesting for 100% of the shares underlying this option will occur upon the earlier of (i) the first anniversary of the grant date (June 25, 2026) or (ii) the date of the 2026 Annual Meeting, contingent on Ms. Schulz's continued service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation disclosure, not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to align leadership incentives with long-term company growth and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in the biotech sector.
• The specific size of the grant (21,950 options) and the exercise price ($2.05) would typically be evaluated against Senti Biosciences' peer group compensation policies and the company's overall market capitalization and stage of development to determine if it is within industry norms. This document alone does not provide sufficient data for such a detailed comparative assessment.

Corporate Governance

Related Party Transactions

• The stock option grant to Director Fran Schulz constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors. This is a standard form of equity compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the 2026 Annual Meeting, subject to continued service.

Key Dates

Keywords

Senti Biosciences, SNTI, Stock Option Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Corporate Governance